Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.1K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic performance and interchangeability of two commercial anti-RSV-IgG and IgA ELISAs across clinically relevant populations.

Microbiology spectrum·2026
Same author

Stress granule phase separation in stress-responsive cytosolic extract-in-oil droplets.

Nature communications·2026
Same author

Deprescribing of proton pump inhibitors in internal medicine in-patients: A retrospective observational study.

Exploratory research in clinical and social pharmacy·2026
Same author

Quantifying diclofenac - proven in theory, problematic in practice.

Bioanalysis·2026
Same author

Referral pathway for adults with chronic cough in Switzerland from a Delphi-based consensus study.

Postgraduate medicine·2026
Same author

Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-up.

Research and practice in thrombosis and haemostasis·2026

Related Experiment Video

Updated: Feb 28, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

11.1K

Leucopenia associated with metamizole: a case-control study.

Lea Blaser1, Hala Hassna1, Sarah Hofmann1

  • 1Division of Clinical Pharmacology and Toxicology, University and University Hospital Basel, Switzerland.

Swiss Medical Weekly
|June 22, 2017
PubMed
Summary
This summary is machine-generated.

Metamizole use can lead to leucopenia. Risk factors include a history of allergies, prior leucopenic episodes, hepatitis C infection, and concurrent use of cytostatic agents.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.6K

Related Experiment Videos

Last Updated: Feb 28, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

11.1K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.6K

Area of Science:

  • Pharmacology and Toxicology
  • Hematology

Background:

  • Metamizole is a widely used analgesic and antipyretic.
  • Leucopenia is a potential adverse effect of metamizole, necessitating identification of associated risk factors.

Purpose of the Study:

  • To investigate potential risk factors for developing leucopenia in patients using metamizole.

Main Methods:

  • A retrospective case-control study was conducted.
  • Cases of metamizole-associated leucopenia were compared with matched controls who received metamizole without complications.

Main Results:

  • A history of allergies and previous leucopenic episodes were more common in cases.
  • Hepatitis C infection prevalence was higher in cases (9%) versus controls (1%).
  • Concomitant cytostatic agent use was significantly higher in non-postoperative cases.

Conclusions:

  • History of allergies, prior leucopenia, hepatitis C infection, and concomitant cytostatic agents are identified as potential risk factors for metamizole-induced leucopenia.